Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

Pediatric Infectious Disease Journal

Volumn 26, Issue 7, 2007, Pages 619-628

  Tam, John S ^a,m   Capeding, Maria Rosario Z ^b   Lum, Lucy Chai See ^c   Chotpitayasunondh, Tawee ^d   Jiang, Zaifang ^e   Huang, Li Min ^f   Lee, Bee Wah ^g   Qian, Yuan ^h   Samakoses, Rudiwilai ⁱ   Lolekha, Somsak ^j   Rajamohanan, K Pillai ^k   Narayanan, S Noel ^k   Kirubakaran, Chellam ^l   Rappaport, Ruth ^m   Razmpour, Ahmad ^m   Gruber, William C ^m   Forrest, Bruce D ⁿ  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^d QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^h CAPITAL INSTITUTE OF PEDIATRICS   (China)

ⁱ PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^j Charoen Krung Pracharak Hospital   (Thailand)

^k GOVERNMENT MEDICAL COLLEGE   (India)

^l CHRISTIAN MEDICAL COLLEGE   (India)

^m WYETH RESEARCH   (United States)

ⁿ Wyeth Vaccines Research   (Japan)

more..

Author keywords

Children; Influenza; Live attenuated; Vaccine

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; PLACEBO; TRIPLE VACCINE;

AGE DISTRIBUTION; ANTIGENICITY; APPETITE; ARTICLE; ASIA; BRONCHITIS; BRONCHOSPASM; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STOMACH PAIN; VIRUS CULTURE; VIRUS STRAIN; VOMITING;

ADAPTATION, PHYSIOLOGICAL; ASIA; CHILD, PRESCHOOL; COLD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; ORTHOMYXOVIRIDAE; VACCINES, ATTENUATED;

EID: 34347361688     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e31806166f8     Document Type: Article

References (37)

1. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147-152.
2. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-8):1-40.
3. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;344:889-896.
4. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369-1373.
5. Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol. 2005;161:303-306.
6. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr Infect Dis J. 1997;16:1065-1068.
7. Hurwitz ES, Haber M, Chang A, et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis. 2000;182:1218-1221.
8. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23:189-197.
9. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733-740.
10. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000;284:1677-1682.
11. CDC's advisory committee recommends expanded influenza vaccinations for children. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/od/oc/media/pressrel/r060223. htm. Accessed March 10, 2006.
12. Huq F, Rahman M, Nahar N, et al. Acute lower respiratory tract infection due to virus among hospitalized children in Dhaka, Bangladesh. Rev Infect Dis. 1990;12(suppl 8):S982-S987.
13. Zeng DL, Zhang ZJ, Wang ZL, Zhang JN, Yang ML. Surveillance of acute respiratory infections in three kindergartens in Beijing. Chin Med J (Engl). 1988;101:787-792.
14. Doraisingham S, Goh KT, Ling AE, Yu M. Influenza surveillance in Singapore: 1972-1986. Bull World Health Organ. 1988;66:57-63.
15. Chiu SS, Lau YL, Chan KH, Wong WH, Peiris JS. Influenza-related hospitalizations among children in Hong Kong. N Engl J Med. 2002;347:2097-2103.
16. van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine. 2003;21:1780-1785.
17. Hampson AW. Epidemiological data on influenza in Asian countries. Vaccine. 1999;17(suppl 1):S19-S23.
18. Tseng RK, Chen HY, Hong CB. Influenza virus infections in Taiwan from 1979 to 1995. Jpn J Med Sci Biol. 1996;49:77-93.
19. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine. 2003;21:1762-1768.
20. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-1663.
21. Recommended composition of influenza virus vaccines for use in the 2006 influenza season. Wkly Epidemiol Rec. 2005;80:342-347.
22. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol. 1989;146:107-116.
23. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175.
24. Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003;158:305-311.
25. Centers for Disease Control and Prevention (CDC). Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season. MMWR Morb Mortal Wkly Rep. 2000;49:619-622.
26. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2000-2001 season. Wkly Epidemiol Rec. 2000;75:61-65.
27. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1405-1412.
28. Cheng SM, Vainionpaa R, Zhao P, et al. Detection of influenza B in clinical specimens: comparison of high throughput RT-PCR and culture confirmation. Virus Res. 2004;103:85-90.
29. Chi XS, Bolar TV, Zhao P, et al. Molecular evolution of human influenza A/H3N2 virus in Asia and Europe from 2001 to 2003. J Clin Microbiol. 2005;43:6130-6132.
30. King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001;20:1124-1131.
31. Palmer DF, Coleman MT, Dowdle WR, Schild GC. Advanced Laboratory Techniques for Influenza Diagnosis (Immunology Series No. 6). Washington, DC: US Department of Health, Education, and Welfare; 1975.
32. Belshe R. Comparison of the efficacy and safety of cold-adapted influenza vaccine, trivalent (CAIV-T) with trivalent inactivated influenza vaccine (TIV) in children 6 to 59 months of age. Paper presented at: Pediatric Academic Societies' 2006 Annual Meeting, San Francisco, CA, April 29-May 2, 2006.
33. Vesikari T. Efficacy and safety of a cold-adapted, live attenuated, trivalent influenza vaccine (CAIV-T) in children aged 6 to <36 months attending day care centers in Europe and Israel. Paper presented at: Pediatric Academic Societies' 2005 Annual Meeting, Washington, DC, May 14-17, 2005. Abstract 1582.
34. Fleming D, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-869.
35. Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Inf Dis J. 2006;25:870-879.
36. Belshe RB, Edwards KM, Vesikari T, et al. Comparative safety and efficacy of live attenuated and inactivated influenza vaccines in infants and young children. N Engl J Med. 2007;356:685-689.
37. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138-144.